Lupin Enters US Market with Generic Sugammadex Injection

Lupin Limited has launched Sugammadex Injection in the US market following approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA).

The product, introduced by Lupin as single-dose vials in 200 mg/2 mL and 500 mg/5 mL strengths, is bioequivalent and therapeutically equivalent to BRIDION (Sugammadex) Injection of Merck Sharp & Dohme LLC.

Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.